$UNH Reversal trade off strong support in UnitedHealth
Possible entry level $222 = Target price $247 = Stop loss $212
P/E ratio 16.32 which is very reasonable.
Yield 1.98%
Average analyst price target $291 | Buy rating
Latest analyst commentary
Barclays analyst Steven Valiquette maintained a Buy rating on UnitedHealth yesterday and set a price target of $260.00. The company’s shares closed last Monday at $220.11, close to its 52-week low of $208.07.
According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.7% and a 47.0% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and Capital Senior Living.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $298.45, representing a 35.6% upside. In a report issued on September 26, Morgan Stanley also maintained a Buy rating on the stock with a $294.00 price target.
Sourse Smarter analyst
Company profile
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health services business serving the broad health care marketplace, including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the health care industry. The OptumRx segment provides pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.
P/E ratio 16.32 which is very reasonable.
Yield 1.98%
Average analyst price target $291 | Buy rating
Latest analyst commentary
Barclays analyst Steven Valiquette maintained a Buy rating on UnitedHealth yesterday and set a price target of $260.00. The company’s shares closed last Monday at $220.11, close to its 52-week low of $208.07.
According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.7% and a 47.0% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Patterson Companies Inc, and Capital Senior Living.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $298.45, representing a 35.6% upside. In a report issued on September 26, Morgan Stanley also maintained a Buy rating on the stock with a $294.00 price target.
Sourse Smarter analyst
Company profile
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health services business serving the broad health care marketplace, including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the health care industry. The OptumRx segment provides pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.